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As the patient load at antiretroviral clinics increases 
with the drive to meet the goals of the HIV, AIDS and 
STI Strategic Plan for South Africa, 2007 - 2011, there is 
a need to conduct research to enable the development 
of population-specific guidelines and policies. An un-
derstanding of the effect of highly active antiretroviral 
therapy (HAART) on various aspects of health of HIV-in-
fected individuals in South Africa, including nutritional 
status, is needed. 
Although there are data available from some African 
countries1 indicating that HAART may result in changes 
in body composition and other anthropometric meas-
ures, no such figures for South African adults have been 
published in the peer-reviewed literature.
This prospective study was therefore carried out to in-
vestigate the changes, if any, that occur in HIV-infected 
women receiving HAART in a primary health care set-
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Background and objectives. An understanding of the effect of highly active antiretroviral therapy (HAART) on 
various aspects of health, including nutritional status, is needed to ensure that population-specific guidelines 
can be developed for South Africa. This study aimed to investigate the changes in body composition and other 
anthropometric measures that occur in HIV-infected women after the initiation of HAART and to explore the 
relationship between these measures and CD4 lymphocyte count. 
Design and setting. A longitudinal study was carried out at the Umkhumbane Community Health Centre, 
KwaZulu-Natal. 
Subjects. 30 HIV-infected adult women who started HAART between March 2007 and October 2007.
Methods. Anthropometric measurements and bioelectrical impedance analysis were performed at baseline and 24 
weeks after commencing HAART. CD4 lymphocyte counts were done at baseline and at the 24-week visit.
Results. There was a statistically significant increase in all anthropometric measures except waist-hip ratio and lean 
body mass. The mean weight change (± standard deviation) was 3.4±5.8 kg (p=0.006). Mean body mass index (BMI) 
(kg/m2) increased from 25.6±5.7 to 27.3±5.6 (p=0.007). Seventy per cent of subjects gained weight, 18.5% had a 
stable weight and 11.1% lost weight. Subjects with lower CD4 lymphocyte counts experienced greater increases 
in weight, BMI, fat mass and body fat percentage. No significant association was found between anthropometric 
changes and change in CD4 count between baseline and the 24-week visit.
Conclusions. The findings demonstrate the value of including circumference measurements and body composition 
techniques as part of nutritional status assessment. Research is needed to determine the best methods of bringing 
about favourable anthropometric changes to enhance the health of patients on HAART.
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ting in KwaZulu-Natal and to investigate associations 




The study sample was drawn from patients on the MTCT-
Plus Programme at Umkhumbane Community Health 
Centre, Cato Manor, KwaZulu-Natal. The majority of the 
patients live in the Cato Manor urban informal settle-
ments, where the homes consist of shacks and low-cost 
housing, many without running water, electricity or a 
water-borne sewage system. The clinic serves a predom-
inantly Zulu population. The first 30 women, 18 years 
of age or older, who started HAART for the first time 
between March 2007 and October 2007; met the eligibil-
ity criteria; and provided written informed consent were 
consecutively enrolled into the study. Exclusion criteria 
included current pregnancy or recent pregnancy (deliv-
ery in the previous 8 weeks) and any malignant disease. 
Individuals were eligible to commence HAART if they had 
a CD4 lymphocyte count of below 200 cells/µl, World 
Health Organization (WHO) clinical stage 4 disease irre-
spective of CD4 lymphocyte count, or WHO clinical stage 
3 disease with a CD4 count of 200 - 350 cells/µl.2
Ethics approval was obtained from the Committee for 
Human Research at Stellenbosch University and the 
Bioethics Committee of the Nelson R Mandela School of 
Medicine, University of KwaZulu-Natal. 
STUDy pROCEDURES
All measurements were performed on the day HAART was 
commenced and then again after 24 weeks on HAART. 
Anthropometric measurements were performed by the 
principal investigator and included weight, height, mid-
upper arm circumference (MUAC), waist circumference 
and hip circumference. Standardised techniques and the 
same equipment were used for all measurements. The 
measurements were taken in duplicate and the mean of 
the two measurements was used.3 
Weight was measured using an electronic scale and 
recorded to the nearest 0.1 kg. Subjects were weighed 
without shoes and wearing only light clothing. Height 
was measured using a stadiometer (SECA 225). Subjects 
were measured without shoes and standing in an upright 
position. The head was positioned in the Frankfort hori-
zontal plane and the subjects were asked to relax their 
shoulders and stand with their arms at their sides.3 
MUAC was measured on the right side for all subjects. 
The measurement was taken at the mid-point between 
the top of the acromion process of the scapula and the 
olecranon process of the ulna and was measured with 
the arm hanging freely at the subject’s side.4 Waist cir-
cumference was measured with the tape measure posi-
tioned around the abdomen at the mid-point between 
the lowest rib and the iliac crest after the subject had 
gently exhaled. Hip circumference was measured as the 
maximal circumference over the buttocks. Circumfer-
ence measurements were performed using a flexible, 
inelastic tape measure (SECA). Height and circumference 
measurements were recorded to the nearest 0.1 cm.4 
The body mass index (BMI) was calculated by dividing 
the weight of the subject by their height squared (kg/m2) 
and the waist-hip ratio (WHR) was calculated by dividing 
the waist circumference by the hip circumference. The 
measurements obtained, as well as these indices, were 
then used to classify the individuals according to the 
WHO cut-off values.5 Subjects were classified into the 
following BMI categories: underweight (<18.5); normal 
weight (18.5 - 24.9); overweight (25.0 - 29.9) and obese 
(≥30). A WHR greater than 0.85 indicates accumulation 
of abdominal fat, and a waist circumference of ≥80 cm 
and ≥88 cm identifies individuals at increased risk and 
substantially increased risk of cardiovascular disease, re-
spectively.5 
Bioelectrical impedance analysis (BIA) was performed 
using a quad-frequency analyser (Bodystat® QuadScan 
4000 Hydration/Body Composition Monitoring Unit, 
Isle of Man, UK), which is a battery-operated unit that 
is connected to the body by electrodes, to allow a small 
electric current to pass through the body. A measure-
ment of the impedance to the current in the body is then 
obtained and is used to estimate total body water (TBW) 
and calculate lean body mass (LBM) and body fat us-
ing regression equations. To enhance reliability, all the 
assessments were performed by the principal investiga-
tor and the analyser was calibrated before each analy-
sis using the calibrator supplied by the manufacturer. 
Measurements were performed according to the manu-
facturer’s instructions (Bodystat® QuadScan 4000 User’s 
Guide) and using standardised procedures and electrode 
placements.6 
It could not be assumed that the BIA equations built into 
the analyser by the manufacturer were suitable for use in 
black African HIV-infected women in South Africa, so we 
developed our own population-specific equation to cal-
culate LBM as part of an ancillary study attached to the 
same study population. LBM was derived from the TBW, 
which was measured by the deuterium isotope dilution 
method, and impedance values were obtained using the 
abovementioned analyser in a sample of 50 HIV-infected 
women from the same study population. Stepwise mul-
tiple regression analysis was used to develop the predic-
tion equation and the correlation coefficient was 0.873, 
showing a good fit between the values obtained from 
the equation using impedance values from the BIA and 
the deuterium dilution method. The subjects’ impedance 
values obtained from the BIA were then used in the pre-
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diction equation to calculate the LBM of the subjects 
in the current study. Fat mass (FM) was calculated by 
subtracting the LBM from total body weight. Body fat 
percentage (BF%) was calculated by dividing fat mass by 
body weight and multiplying the value by 100. 
Viral loads were performed by in vitro NASBA® HIV-1 as-
say using the Nuclisens Easy-Q-HIV-1 Viral Load Method 
(bioMérieux SA, Mercy L’Etoile, France), and CD4 lym-
phocyte counts were done by flow-cytometry using the 
BD Facscalibur Method (Becton Dickinson, San Jose, CA, 
USA). A viral load of less than 25 copies/ml was consid-
ered undetectable as this is the lower detection limit of 
the Nuclisens Easy-Q-HIV-1 Viral Load Assay. 
The HAART regimens used by the MTCT-Plus Programme 
are consistent with the WHO guidelines.2 All subjects 
were prescribed the first-line HAART regimen, which is 
based on a combination of one non-nucleoside reverse 
transcriptase inhibitor (NNRTI), either nevirapine (NVP) 
or efavirenz (EFV), with two nucleoside analogue reverse 
transcriptase inhibitors (NRTIs), which consisted of lami-
vudine (3TC) and either stavudine (D4T) or zidovudine 
(AZT). 
Although the national guidelines made provision for 
food parcels for patients on HAART, owing to provin-
cial budgetary constraints the supply at the clinic was 
inconsistent and none of our patients was able to ac-
cess these food parcels for any significant time period. 
No incentives were provided to patients to participate in 
the study, as all measurements were done during their 
routine visits.
STATISTICAL ANALySES
Continuous variables were summarised using means 
and standard deviations (SDs) and were compared 
using paired t-tests. Categorical data were summarised 
using proportions and percentages. For the purpose of 
analysis, subjects with an undetectable viral load were 
assigned a viral load of 24 copies/ml or 1.4 log10 copies/
ml. Subjects were also categorised according to their 
body weight changes between baseline and the 24-
week visit as follows: weight loss, weight gain or weight 
stable. Correlation analysis was performed to investigate 
the relationship between variables and was expressed 
using Spearman’s correlation coefficient. A p-value of 
less than 0.05 was considered statistically significant. 
The statistical analyses were carried out by a statistician 




A total of 30 subjects were enrolled into the study. The 
participants had a mean age (± SD) of 30.9±5.6 years. 
Table I presents the baseline characteristics of the 30 
women enrolled into the study, including the baseline 
socio-demographic, anthropometric and laboratory pa-
rameters.
The mean weight (± SD) of the subjects at baseline was 
63.7±16.0 kg (range 40.5 - 109.6 kg), the mean BMI was 
25.6±5.7 (range 14.5 - 37.8) and the mean BF% was 
32.2±9.7% (range 7.1 - 48.0%). Only 2 (6.7%) of the sub-
jects were underweight (BMI <18.5) at baseline, while 
13 (43.3%) were of normal weight (BMI 18.5 - 24.9), 9 
(30.0%) were overweight (BMI 25 - 29.9) and 6 (20.0%) 
were obese (BMI >30). 
CHANgES IN ANTHROpOMETRIC MEASUREMENTS 
AfTER THE INITIATION Of HAART
Twenty-seven of the 30 subjects completed the 24-week 
follow-up period. Two subjects died and one was lost to 
follow-up before the 24-week visit. The mean weight, 
BMI, MUAC, waist and hip circumferences and WHR at 
baseline and 24 weeks after the initiation of HAART are 
set out in Table II. The values for LBM, FM and BF%, as 
determined by BIA, are also presented, as are the mean 
changes for each of the anthropometric measures.
Overall, there was a statistically significant increase in all 
anthropometric measures after the initiation of HAART, 
except for WHR and LBM (Table II). The mean weights 
(± SD) at baseline and after 24 weeks were 63.7±16.0 
kg and 68.2±15.0 kg, respectively. This was an average 
weight change of 3.4±5.8 kg (p=0.006). A considerable 
proportion of the subjects (50%; N=15) had a BMI above 
the upper limit of the normal range at baseline, and this 
increased to 67% (N=18) by the 24-week visit, with 30% 
(N=8) of these subjects being obese. The mean BMI of 
the subjects at baseline was 25.6±5.7, and this increased 
to 27.3±5.6 by the 24-week visit (p=0.007). 
Although the majority of the subjects gained weight 
(N=19; 70.4%) after 24 weeks on HAART, 3 (11.1%) lost 
weight and 5 (18.5%) had a body weight that remained 
stable. In those who gained weight the average weight 
gain was 5.6±5.3 kg (p=0.000) (range 1.2 - 24.7 kg). The 
subjects who lost weight, lost an average of 4.6±1.6 kg 
(p=0.037) (range 2.9 - 6.0 kg) by the 24-week visit. 
The subjects experienced a mean (± SD) increase in CD4 
lymphocyte count of 120±114 cells/µl (p=0.000) and 
a mean decrease in viral load of log 2.7±1.2 copies/ml 
(p=0.000) between baseline and the 24-week follow-up 
visit. 
Of the 19 subjects who gained weight between baseline 
and the 24-week visit, 68.4% (N=13) gained mostly FM 
and 32.6% (N=6) gained mostly LBM. Three of the 5 sub-
jects with a stable body weight lost FM and gained LBM, 
while the proportions of FM and LBM remained stable 
in the other 2. In the 3 subjects who lost weight after 
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commencing HAART, the weight loss consisted mainly of 
LBM (4.8±3.8 kg; p=0.159). 
Six subjects had evidence of disproportionate gains and 
losses in body circumference measurements. Three sub-
jects experienced an increase in waist circumference and 
a simultaneous decrease in hip circumference, and 3 
experienced an increase in waist circumference with a 
simultaneous decrease in hip circumference and MUAC. 
RELATIONSHIp BETwEEN ANTHROpOMETRIC 
MEASURES AND CD4 LyMpHOCyTE COUNT
A statistically significant negative linear correlation was 
found between CD4 lymphocyte count at baseline and 
changes in weight (rs=–0.40; p=0.04), BMI (rs=–0.40; 
p=0.04), FM (rs=–0.53; p=0.00) and BF% (rs=–0.41; 
p=0.02) between baseline and after 24 weeks on HAART 
but not for MUAC, waist circumference, hip circumfer-
ence, WHR or LBM. Correlation analysis found no signifi-
cant linear association between changes in weight, BMI, 
MUAC, waist circumference, hip circumference, WHR, 
LBM, FM or BF% between baseline and the 24-week 
follow-up visit and changes in CD4 lymphocyte count. 
Change in CD4 lymphocyte count between baseline and 
24 weeks was not significantly associated with any of 
the baseline anthropometric measurements, except for 
MUAC with which there was a modest but significant 
positive correlation (rs=0.40; p=0.04). 
DISCUSSION
In this study, subjects underwent significant changes in 
most of the anthropometric measures after just 24 weeks 
on HAART. Mean weight, BMI, MUAC, waist circumfer-
ence, hip circumference, FM and BF% all increased sig-
nificantly after the initiation of HAART. Only mean WHR 
and LBM did not increase significantly. 
Comparison of the results of this study with those of 
previous studies is complicated, as the majority of the 
studies that have investigated the effect of HAART on 
anthropometric measures have been carried out on 
males in developed countries, few longitudinal studies 
have been conducted, and the methodology used has 
differed considerably.7-11 
Although the majority of the subjects gained weight 
during the follow-up period, some had a body weight 
which remained stable and others lost weight. This is in 
accordance with the results of the study by Saghayam 
et al.7 Some of our subjects gained significant amounts 
of weight (range 1.2 - 24.7 kg), with the majority of the 
weight gain in most subjects being attributable to an in-
crease in FM, which is consistent with the findings of 
Silva et al.12  Future studies should examine the health 
implications of gaining FM in subjects on HAART in 
South Africa. 
Some studies have reported increases in LBM after the 
initiation of HAART,10,11 which is associated with im-
proved functional performance,10 and identifying ways 
of improving LBM that are both effective and feasible 
may therefore prove valuable. Possible explanations for 
the improvement in LBM observed in some of the sub-
jects in this study with a stable body weight include im-
provements in muscle mass as a result of an increase in 
activity levels associated with an overall improvement in 





No piped water in home 11 (36.7)
No electricity in home 14 (46.7)
Previous pregnancy 30 (100)
No. of previous pregnancies  
1 6 (20.0)
2 15 (50.0)
3 or more 9 (30.0)
Initial HAART regimen
AZT, 3TC, NVP 17 (53.3)
AZT, 3TC, EFV 8 (26.7)
d4T, 3TC, EFV 5 (16.7)
Weight (kg) 63.7±16.0 
BMI (kg/m2) 25.6±5.7
<18.5 (underweight) 2 (6.7)
18.5 - 24.9 (normal weight) 13 (43.3)
25 - 29.9 (overweight) 9 (30.0)
≥30 (obese) 6 (20.0)
MUAC (cm) 28.3±5.1
Waist circumference (cm) 84.5±11.6 
Hip circumference (cm) 98.6±13.2 
WHR 0.86±0.05 
Waist circumference ≥80 cm 9 (30.0)
Waist circumference ≥88 cm 9 (30.0)




CD4 cell count (cells/µl) 164±69
Viral load (log10 copies/ml) 4.5±1.2 
Note: Data are number (%) of patients or mean ± SD. 
HAART = highly active antiretroviral therapy; AZT = zidovudine; 3TC = lami-
vudine; NVP = nevirapine; EFV = efavirenz; d4T = stavudine; BMI = body mass 
index; MUAC = mid-upper arm circumference; WHR = waist-hip ratio; LBM = 
lean body mass; FM = fat mass; BF% = body fat percentage.
TABLE I. BASELINE CHARACTERISTICS Of THE 30 
wOMEN ENROLLED INTO THE STUDy
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subjects who lost weight the loss was composed mostly 
of LBM, and this is well known to be prognostically un-
favourable.6 Two of the 3 subjects who lost weight were 
known to live in food-insecure households and the other 
reported intentional weight loss.
From the results, it can be seen that the baseline CD4 
lymphocyte count before HAART initiation appears to 
have an inverse relationship with change in BMI, FM, 
and BF% between baseline and the 24-week visit. Sub-
jects with lower CD4 lymphocyte counts experienced 
greater increases in weight, BMI, FM and BF%. The find-
ing that subjects with more severe immunosuppression 
at baseline experienced greater increases in body weight 
on HAART is supported by the results of the study by 
Shikuma et al.10 In a study by Mwamburi et al.,9 changes 
in CD4 lymphocyte count after the initiation of HAART 
were associated with changes in weight, but others have 
found no relationship.7 In our study the anthropometric 
changes were not significantly correlated with changes 
in CD4 lymphocyte count. Larger studies of longer dura-
tion should be carried out to examine the changes in 
anthropometric measures that occur after the initiation 
of HAART and to describe more clearly the relationship 
between anthropometric measures and immunological 
response as well as the overall health of subjects.
Another noteworthy observation was the disproportion-
ate change in circumference measures seen in some 
subjects. This may indicate fat redistribution, during 
which it is common for subjects to experience fat loss 
from the buttocks and extremities, and/or an increase in 
abdominal FM.13 
The finding that such a large proportion of the subjects 
in this study had a BMI above the upper limit of the nor-
mal range and that a considerable number had abdomi-
nal fat accumulation, as indicated by the WHR and waist 
circumference measurements, is cause for concern, 
firstly because of the well-known health risks associated 
with overweight and obesity in the general population, 
which include type 2 diabetes mellitus, hypertension, 
respiratory difficulties and dyslipidaemia.5 Secondly, an 
Characteristic Baseline (N=30) 24 weeks (N=27) Change p-value
Weight (kg) 63.7±16.0 68.2±15.0 3.4±5.8 0.006
BMI (kg/m2) 25.6±5.7 27.3±5.6 1.4±2.5 0.007
MUAC (cm) 28.4±5.1 29.8±4.4 1.1±2.1 0.009
Waist circumference (cm) 84.5±11.6 88.3±11.2 3.3±6.4 0.012
Hip circumference (cm) 98.6±13.2 102.1±11.8 2.6± 4.9 0.011
WHR 0.86±0.05 0.86±0.07 0.01±0.04 0.294
LBM (kg) 41.9±5.7 43.0±6.2 0.7±3.2 0.262
FM (kg) 21.8±11.2 25.2±9.5 2.7±4.5 0.005
BF% 32.2±9.7 35.7±7.0 3.0±5.2 0.006
CD4 cell count (cells/µl) 164±69 282±154 120±114 0.000
Viral load (log10 copies/ml) 4.5±1.2 1.7±0.8 –2.7±1.2 0.000
BMI categories
<18.5 (underweight) 2 (6.7) 1 (3.7)
18.5 - 24.9 (normal weight) 13 (43.3) 8 (29.6)
25 - 29.9 (overweight) 9 (30.0) 10 (37.0)  
≥30 (obese) 6 (20.0) 8 (29.6)
Waist circumference ≥80 cm 
baseline
9 (30.0) 9 (33.3)
  
Waist circumference ≥88 cm 
baseline
9 (30.0) 11 (40.7)
WHR >0.85 17 (56.7) 10 (37.0)   
Note: Data are mean ± SD or number (%) of patients.  
HAART = highly active antiretroviral therapy; BMI = body mass index; MUAC = mid-upper arm circumference; WHR = waist-hip ratio; LBM = lean body mass; FM = fat 
mass; BF% = body fat percentage.
TABLE II. ANTHROpOMETRIC AND LABORATORy MEASURES AT BASELINE AND AfTER 24 wEEkS ON HAART
Changes in body.indd   41 12/17/08   3:19:58 PM
S p r i n g  2 0 0 8                                                           T H E  S O U T H E R N  A F R I C A N  J O U R NA L  O F  H I V  M E D I C I N E       42
above-normal BMI may mean that a large proportion of 
HIV-infected individuals may not seek care, and health 
care professionals may not identify individuals for HIV 
testing as a result of the common misconception that 
they are ‘healthy’14 when in fact they may not only be 
HIV-infected but already eligible for HAART. 
Although the risks of overweight and obesity in the HIV-
infected population specifically, and especially in the 
era of HAART, are not known, because of the associa-
tion between overweight and obesity and adverse health 
outcomes in the general population it seems prudent 
to ensure that subjects are cautioned against excessive 
weight gain. The issue of overweight and obesity war-
rants attention, and studies are urgently needed to de-
termine the prevalence and significance of overweight 
and obesity in the HIV-infected population in South Af-
rica. The optimal nutritional advice to be given to over-
weight and obese HIV-infected subjects remains to be 
determined. 
This study had some limitations that need to be ac-
knowledged. Firstly, only females were included in the 
study and the results therefore cannot be generalised to 
male subjects. Secondly, owing to the small sample size 
we were not able to control for potential confounding 
factors such as HAART regimen and clinical parameters, 
and the changes that were observed may therefore have 
been independently associated with other factors not 
analysed. We recommend that future studies include 
both genders and a large enough sample to allow for 
investigation according to HAART regimen, clinical stag-
ing and other morbidity factors to allow for the develop-
ment of widely applicable guidelines. 
In conclusion, the findings of this study demonstrate 
firstly the value of including circumference measure-
ments and body composition assessment techniques as 
part of the assessment of nutritional status. The results 
show that merely following weight changes in subjects 
would mask underlying changes in body composition 
and changes in fat redistribution. We therefore suggest 
that programmes include waist and hip measurements 
and if possible BIA measurements, at least annually or 
ideally at 6-monthly intervals, in order to provide useful 
information to assist in patient management. Secondly, 
this study suggests that given that the majority of sub-
jects who gained weight gained mostly FM and not LBM, 
there is a need for further research to develop interven-
tions such as exercise training programmes to improve 
LBM and decrease abdominal obesity.15 The long-term 
aim of HIV care and treatment programmes should not 
merely be to obtain virological suppression but also to 
improve overall health and quality of life.16,17 
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